Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Immune system versus tumor: shifting the balance in favor of DCs and effective immunity.

Literature DB >> 14991063

Immune system versus tumor: shifting the balance in favor of DCs and effective immunity.

Abstract

Despite the initial excitement over cancer vaccines, the clinical effectiveness of immunotherapy has been disappointing. The suppressive milieu present within established tumors inhibits effective immune responses, although new strategies are emerging to manipulate the local tumor microenvironment and shift the balance back to a proinflammatory environment, promote DC activation, and enhance tumor immunity.

Entities: Disease

Mesh：

Substances：
Cancer Vaccines

Year: 2004 PMID： 14991063 PMCID： PMC351327 DOI： 10.1172/JCI21148

Source DB: PubMed Journal: J Clin Invest ISSN： 0021-9738 Impact factor: 14.808

16 in total

Review 1. The control of immunity and tolerance by dendritic cell.

Authors: R M Steinman
Journal: Pathol Biol (Paris) Date: 2003-03

Review 2. Does the immune system see tumors as foreign or self?

Authors: Drew Pardoll
Journal: Annu Rev Immunol Date: 2001-12-19 Impact factor: 28.527

3. Inhibition of cytolytic T lymphocyte proliferation by autologous CD4+/CD25+ regulatory T cells in a colorectal carcinoma patient is mediated by transforming growth factor-beta.

Authors: Rajasekharan Somasundaram; Lutz Jacob; Rolf Swoboda; Laura Caputo; Hong Song; Saroj Basak; Dimitri Monos; David Peritt; Francesco Marincola; Dewei Cai; Brigitte Birebent; Ellen Bloome; Jin Kim; Klara Berencsi; Michael Mastrangelo; Dorothee Herlyn
Journal: Cancer Res Date: 2002-09-15 Impact factor: 12.701

Review 4. Cancer vaccines: between the idea and the reality.

Authors: Olivera J Finn
Journal: Nat Rev Immunol Date: 2003-08 Impact factor: 53.106

5. Transfection of macrophage inflammatory protein 1 alpha into B16 F10 melanoma cells inhibits growth of pulmonary metastases but not subcutaneous tumors.

Authors: Hendrik W van Deventer; Jonathon S Serody; Karen P McKinnon; Casey Clements; W June Brickey; Jenny P-Y Ting
Journal: J Immunol Date: 2002-08-01 Impact factor: 5.422

Review 6. Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity.

Authors: Teresa Ramirez-Montagut; Mary Jo Turk; Jedd D Wolchok; José A Guevara-Patino; Alan N Houghton
Journal: Oncogene Date: 2003-05-19 Impact factor: 9.867

7. A controlled trial of a human papillomavirus type 16 vaccine.

Authors: Laura A Koutsky; Kevin A Ault; Cosette M Wheeler; Darron R Brown; Eliav Barr; Frances B Alvarez; Lisa M Chiacchierini; Kathrin U Jansen
Journal: N Engl J Med Date: 2002-11-21 Impact factor: 91.245

8. Induction of potent antitumor immunity by in situ targeting of intratumoral DCs.

Authors: Katsuyoshi Furumoto; Luis Soares; Edgar G Engleman; Miriam Merad
Journal: J Clin Invest Date: 2004-03 Impact factor: 14.808

Review 9. Tumors as elusive targets of T-cell-based active immunotherapy.

Authors: Francesco M Marincola; Ena Wang; Meenhard Herlyn; Barbara Seliger; Soldano Ferrone
Journal: Trends Immunol Date: 2003-06 Impact factor: 16.687

10. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma.

Authors: Udaya K Liyanage; Todd T Moore; Hong-Gu Joo; Yoshiyuki Tanaka; Virginia Herrmann; Gerard Doherty; Jeffrey A Drebin; Steven M Strasberg; Timothy J Eberlein; Peter S Goedegebuure; David C Linehan
Journal: J Immunol Date: 2002-09-01 Impact factor: 5.422

17 in total

1. Effective modulation of CD4(+)CD25 (+high) regulatory T and NK cells in malignant patients by combination of interferon-α and interleukin-2.

Authors: Guangxian Liu; Wuwei Yang; Mei Guo; Xiaoqing Liu; Naixiang Huang; Dingfeng Li; Zefei Jiang; Wenfeng Yang; Weijing Zhang; Hang Su; Zhiqing Liu; Tieqiang Liu; Dongmei Wang; Shan Huang; Bo Yao; Qiuhong Man; Lijuan Qiu; Xuedong Sun; Yuying Sun; Bing Liu
Journal: Cancer Immunol Immunother Date: 2012-06-22 Impact factor: 6.968

Review 2. Human leukocyte antigen (HLA) class I defects in head and neck cancer: molecular mechanisms and clinical significance.

Authors: Robert L Ferris; Jennifer L Hunt; Soldano Ferrone
Journal: Immunol Res Date: 2005 Impact factor: 2.829

Review 3. Use of tumour-responsive T cells as cancer treatment.

Authors: Mary L Disis; Helga Bernhard; Elizabeth M Jaffee
Journal: Lancet Date: 2009-02-21 Impact factor: 79.321

4. Rehmannia glutinosa polysaccharide induces toll-like receptor 4 dependent spleen dendritic cell maturation and anti-cancer immunity.

Authors: Li Xu; Minseok Kwak; Wei Zhang; Ling Zeng; Peter Chang-Whan Lee; Jun-O Jin
Journal: Oncoimmunology Date: 2017-05-12 Impact factor: 8.110

5. Dendritic cell infiltration and prognosis of human hepatocellular carcinoma.

Authors: Xiao-Yan Cai; Qiang Gao; Shuang-Jian Qiu; Sheng-Long Ye; Zhi-Quan Wu; Jia Fan; Zhao-You Tang
Journal: J Cancer Res Clin Oncol Date: 2006-01-19 Impact factor: 4.553

6. Targeting the intratumoral dendritic cells by the oncolytic adenoviral vaccine expressing RANTES elicits potent antitumor immunity.

Authors: Natalia Lapteva; Melissa Aldrich; David Weksberg; Lisa Rollins; Tatiana Goltsova; Si-Yi Chen; Xue F Huang
Journal: J Immunother Date: 2009 Feb-Mar Impact factor: 4.456

10. Increased expression of tumor-associated antigens in pediatric and adult ependymomas: implication for vaccine therapy.

Authors: Jacky T Yeung; Ronald L Hamilton; Hideho Okada; Regina I Jakacki; Ian F Pollack
Journal: J Neurooncol Date: 2012-11-21 Impact factor: 4.130